<SEC-DOCUMENT>0001553350-18-001375.txt : 20181221
<SEC-HEADER>0001553350-18-001375.hdr.sgml : 20181221
<ACCEPTANCE-DATETIME>20181221172443
ACCESSION NUMBER:		0001553350-18-001375
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181221
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181221
DATE AS OF CHANGE:		20181221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		181250562

	BUSINESS ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-839-5200

	MAIL ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ameh_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Current Report</TITLE>
<META NAME="date" CONTENT="11/09/2018">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<A NAME="eolPage1"></A><A NAME="V242690_8K_HTM"></A><A NAME="V242690_8K_HTM_EOLPAGE1"></A><A NAME="FIS_TOP_OF_DOCUMENT"></A><A NAME="V242690_8K_HTM_V241347_8K_HTM"></A><A NAME="FIS_FORM"></A><A NAME="FIS_UNIDENTIFIED_TABLE"></A><P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:2.2px; padding-bottom:4px; border-bottom:4px solid #000000" align=right>&nbsp;</P>
<P style="margin:0px; padding-top:4px; border-top:1.333px solid #000000" align=right>&nbsp;</P>
<P style="margin:0px; font-size:12pt" align=center><B>UNITED STATES</B></P>
<P style="margin:0px; font-size:12pt" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px" align=center>&nbsp;</P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>PURSUANT TO SECTION 13 OR 15(d) OF <BR>
THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Date of Report (date of earliest event reported): December 21, 2018</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:18pt" align=center><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Exact name of registrant as specified in its charter)</I></P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=214.4 /><TD width=214.4 /><TD width=214.4 /></TR>
<TR><TD style="margin-top:0px" valign=top width=214.4><P style="margin:0px; padding-right:2.133px" align=center><B>Delaware</B></P>
</TD><TD style="margin-top:0px" valign=top width=214.4><P style="margin:0px; padding-right:2.133px" align=center><B>001-37392</B></P>
</TD><TD style="margin-top:0px" valign=top width=214.4><P style="margin:0px; padding-right:2.133px" align=center><B>46-3837784</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=214.4><P style="margin:0px; padding-right:2.133px; font-size:8pt" align=center><I>(State or Other Jurisdiction of Incorporation)</I></P>
</TD><TD style="margin-top:0px" valign=top width=214.4><P style="margin:0px; padding-right:2.133px; font-size:8pt" align=center><I>(Commission File Number)</I></P>
</TD><TD style="margin-top:0px" valign=top width=214.4><P style="margin:0px; padding-right:2.133px; font-size:8pt" align=center><I>(I.R.S. Employer Identification Number)</I></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Address of principal executive offices) (zip code)</I></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>(626) 282-0288</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Registrant&#146;s telephone number including area code)</I></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>N/A</B></P>
<P style="margin:0px; font-size:8pt" align=center><I>(Former name or former address, if changed since last report)</I></P>
<P style="margin:0px" align=center>&nbsp;</P>
<P style="margin:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD width=48 /><TD width=32.133 /><TD /></TR>
<TR><TD style="margin-top:0px" valign=top width=48><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=32.133><P style="margin:0px; padding-right:1.067px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:1.067px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=48><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=32.133><P style="margin:0px; padding-right:1.067px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:1.067px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=48><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=32.133><P style="margin:0px; padding-right:2.133px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:2.133px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=48><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=32.133><P style="margin:0px; padding-right:2.133px; font-family:Wingdings">&#168;</P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:2.133px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=319 /><TD width=319 /></TR>
<TR><TD style="margin-top:0px" valign=top width=319><P style="margin:0px; text-indent:48px">Emerging growth company&nbsp;<FONT style="font-family:Wingdings">&#168;</FONT></P>
</TD><TD style="margin-top:0px" valign=top width=319><P style="margin:0px">&nbsp;</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<FONT style="background-color:#FFFFFF">&nbsp;</FONT><FONT style="font-family:Wingdings; background-color:#FFFFFF">&#168;</FONT></P>
<P style="margin-top:0px; margin-bottom:2.2px; padding-bottom:4px; border-bottom:1.333px solid #000000">&nbsp;</P>
<P style="margin:0px; padding-top:4px; border-top:4px solid #000000">&nbsp;</P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">&nbsp;</P>
<A NAME="V242690_8K_HTM_EOLPAGE2"></A><A NAME="eolPage2"></A><A NAME="FIS_SECTION_3_SECURITIES_AND_TRADING_MAR"></A><A NAME="FIS_SALE_OF_EQUITY"></A><A NAME="FIS_SECTION_5_CORPORATE_GOVERNANCE"></A><A NAME="FIS_CHANGE_IN_DIRECTORS_OR_PRINCIPAL_OFF"></A><P style="margin:0px"><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD width=71.8 /><TD /></TR>
<TR><TD style="margin-top:0px" valign=top width=71.8><P style="margin:0px"><B>Item 7.01</B></P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px" align=justify><B>Regulation FD Disclosure.</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><FONT style="background-color:#FFFFFF">&nbsp;</FONT></P>
<P style="margin:0px; text-indent:48px" align=justify>On December 21, 2018, Apollo Medical Holdings, Inc. (the &#147;Company&#148;) issued a press release announcing that its subsidiary, APA ACO, Inc. generated $12.96 million in gross savings in its first performance year (2017) under the Next Generation Accountable Care Organization Model sponsored by the Centers for Medicare &amp; Medicaid Services (&#147;CMS&#148;) and, as a result, it will receive $5.90 million in shared savings from CMS. &nbsp;Since the Company already accrued APA ACO, Inc. expenses in 2017, the $5.90 million payment will be recognized as net income in the Company&#146;s 2018 3<SUP>rd</SUP> quarter income statement. &nbsp;A copy of the press release is attached hereto as Exhibit 99.1.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; text-indent:48px" align=justify>This information shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.</P>
<P style="margin:0px" align=justify>&nbsp;</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD width=71.8 /><TD /></TR>
<TR><TD style="margin-top:0px" valign=top width=71.8><P style="margin:0px"><B>Item 9.01</B></P>
</TD><TD style="margin-top:0px" valign=top><P style="margin:0px" align=justify><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:96px; float:left">(d)</P>
<P style="margin-top:0px; margin-bottom:13.333px; text-indent:-2px">Exhibits.</P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD width=91.6 /><TD width=19.6 /><TD /></TR>
<TR><TD style="margin-top:0px; border-bottom:1.333px solid #000000" valign=bottom width=91.6><P style="margin:0px; clear:left" align=center><B>Exhibit No.</B></P>
</TD><TD style="margin-top:0px" valign=bottom width=19.6><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px; border-bottom:1.333px solid #000000" valign=bottom><P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=91.6><P style="margin:0px" align=center>99.1</P>
</TD><TD style="margin-top:0px" valign=top width=19.6><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top><P style="margin:0px; color:#0000FF"><A HREF="ameh_ex99z1.htm"><U>Press Release of Apollo Medical Holdings, Inc., dated December 21, 2018.</U></A><FONT style="color:#000000"></FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:12pt">&nbsp;</P>
<P style="margin:0px"><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>SIGNATURES</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; text-indent:48px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 width=100%><TR height=0 style="font-size:0"><TD /><TD width=48.267 /><TD width=243 /></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:2.133px">Dated: &nbsp;December 21, 2018</P>
</TD><TD style="margin-top:0px" valign=top width=291.267 colspan=2><P style="margin:0px; padding-right:4.8px"><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=291.267 colspan=2><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=48.267><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=243><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; padding-right:1.067px">&nbsp;</P>
</TD><TD style="margin-top:0px" valign=top width=48.267><P style="margin:0px; padding-right:2.133px">By:</P>
</TD><TD style="margin-top:0px; border-bottom:1px solid #000000" valign=top width=243><P style="margin:0px; padding-right:3.133px">/s/ THOMAS S. LAM, M.D.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=48.267><P style="margin:0px; padding-right:2.133px">Name:</P>
</TD><TD style="margin-top:0px" valign=top width=243><P style="margin:0px; padding-right:3.133px">Thomas S. Lam, M.D.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=48.267><P style="margin:0px; padding-right:2.133px">Title:</P>
</TD><TD style="margin-top:0px" valign=top width=243><P style="margin:0px; padding-right:4.8px">Co-Chief Executive Officer</P>
</TD><A NAME="FIS_EXHIBIT_10"></A></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
</BODY>
<!-- EDGAR Validation Code: C6B21408 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ameh_ex99z1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Submission Proof - tv500936</TITLE>
<META NAME="author" CONTENT="Michael Zhao">
<META NAME="date" CONTENT="12/21/2018">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=right><B>EXHIBIT 99.1</B></P>
<P style="margin:0px" align=center><img src="ameh_ex99z1001.jpg" alt="[ameh_ex99z1001.jpg]" align=middle height=117 width=338></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:14pt" align=center><B>APOLLO MEDICAL HOLDINGS ANNOUNCES THAT APA ACO GENERATED $12.96 MILLION IN GROSS SAVINGS IN 2017 AND ACHIEVED $5.90 MILLION IN SHARED SAVINGS FROM THE CENTERS FOR MEDICARE AND MEDICAID SERVICES AS A RESULT</B></P>
<P style="margin:0px" align=justify>&nbsp;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B><I>Alhambra, CA and Glendale, CA &#150; (PR Newswire) &#150; December 21, 2018 &#150; </I></B>Apollo Medical Holdings, Inc. (&#147;ApolloMed&#148;) (NASDAQ: AMEH), an integrated population health management company, announced today that its wholly-owned subsidiary, APA ACO, Inc. (&#147;APA ACO&#148;) generated $12.96 million in gross savings in its first performance year (2017) and that, as a result, it achieved $5.90 million in shared savings from the Centers for Medicare &amp; Medicaid Services (&#147;CMS&#148;).</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>APA ACO was one of 44 Next Generation Accountable Care Organizations (&#147;ACOs&#148;) in the country selected by CMS to participate in the Next Generation ACO Model in 2017. &nbsp;APA ACO was approved to participate in the All-Inclusive Population-Based Payment (&#147;AIPBP&#148;) track, which is the most advanced risk-taking payment model, and was the only Next Generation ACO in the country out of 44 ACOs to participate in the AIPBP track in 2017. &nbsp;Under the AIPBP track, CMS estimates the total annual expenditures for the Next Generation ACO&#146;s patients and then pays that projected amount to the ACO in a per-beneficiary, per-month (&#147;PBPM&#148;) payment. &nbsp;The Next Generation ACO is then responsible for paying all Part A and Part B costs for in-network participating providers and preferred providers with whom it has contracted.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>For 2017, APA ACO&#146;s aggregate benchmark expenditure calculated by CMS was $390.56 million. &nbsp;APA ACO&#146;s actual expenditures were $377.60 million, resulting in gross savings of $12.96 million. &nbsp;CMS then deducted a stop-loss charge of $5.44 million, resulting in gross savings after stop-loss charge of $7.52 million. &nbsp;APA ACO had chosen an 80/20 risk arrangement with CMS, and therefore the net shared savings to APA ACO is $5.90 million. &nbsp;Since ApolloMed had already accrued APA ACO expenses for 2017, all of the $5.90 million payment was recognized as net income in its 2018 3<SUP>rd</SUP> quarter financial statements included in its Form 10Q.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>&#147;We are very proud to have generated $12.96 million in gross savings in our first performance year,&#148; stated Warren Hosseinion, M.D., Co-Chief Executive Officer of ApolloMed. &nbsp;&#147;We believe that this achievement reflects our success in providing high-quality, cost-efficient, coordinated care for our patients.&#148;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>&#147;As the first and only ACO in the country to participate in the AIPBP track and now also managing the care of over one million patients under capitated risk arrangements in our independent practice associations, we believe we are pioneers in the shift of U.S. healthcare from fee-for-service to value-based reimbursements,&#148; stated Thomas Lam, M.D., Co-Chief Executive Officer of ApolloMed.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>&#147;The multi-year investments we have made in ApolloMed&#146;s clinical knowledge base, population health management platform and risk management infrastructure have positioned us to benefit from the ongoing shift to value-based payment models,&#148; stated Kenneth Sim, M.D., Executive Chairman of ApolloMed. &nbsp;&#147;Our integrated model spans the entire inpatient and outpatient care continuum, which is essential for the delivery of quality, cost-efficient care.&#148;</P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B>&nbsp;</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B>About Apollo Medical Holdings, Inc.</B></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt"><FONT style="background-color:#FFFFFF">&nbsp;</FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><FONT style="background-color:#FFFFFF">ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization (&#147;Next Generation ACO&#148;), and its affiliated independent practice associations (&#147;IPAs&#148;) and management services organizations (&#147;MSOs&#148;), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner.&nbsp; Led by a management team with over two decades of experience, ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes Network Medical Management, Inc. (MSO), &nbsp;Apollo Medical Management, Inc. (MSO), ApolloMed Hospitalists, APA ACO&nbsp;(Next Generation ACO), Allied Physicians of&nbsp;California&nbsp;(IPA) and Apollo Care Connect, Inc.</FONT><FONT style="background-color:#FFFFFF"><B> </B></FONT><FONT style="background-color:#FFFFFF">(Digital Population Health Management Platform). ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.&nbsp; For more information, please visit&nbsp;www.apollomed.net.</FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B>&nbsp;</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><B>Forward Looking Statements</B></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>&nbsp;</P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify><FONT style="background-color:#FFFFFF"><I>This press release contains forward-looking statements&nbsp;within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company&#146;s operational focus, strategic growth plans, and merger integration efforts, including APA ACO&#146;s continued participation in the </I></FONT><I>AIPBP track</I><FONT style="background-color:#FFFFFF"><I> and as a Next Generation ACO.&nbsp;Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed.&nbsp;Such statements are based&nbsp;on&nbsp;the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results.&nbsp;Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including without limitation the risk factors discussed in the&nbsp;Company's</I></FONT><FONT style="background-color:#FFFFFF">&nbsp;</FONT><FONT style="background-color:#FFFFFF"><I>Annual Report on Form 10-K filed with the SEC on&nbsp;April 2, 2018.</I></FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=justify>&nbsp;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=center><B>FOR MORE INFORMATION, PLEASE CONTACT:</B></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt" align=center>&nbsp;</P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt"><FONT style="background-color:#FFFFFF"><B>Warren Hosseinion, M.D.<BR>
</B></FONT><FONT style="background-color:#FFFFFF">Co-Chief Executive Officer<BR>
</FONT><FONT style="background-color:#FFFFFF">Apollo Medical Holdings, Inc.<BR>
</FONT><FONT style="background-color:#FFFFFF">(818) 839-5200<BR>
</FONT><FONT style="background-color:#FFFFFF">warrenhoss@apollomed.net</FONT></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt">&nbsp;&nbsp;</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; font-family:Cambria,Times New Roman; font-size:11pt">&nbsp;</P>
<P style="margin:0px" align=center>&nbsp;</P>
<P style="margin:0px" align=center><BR>
<BR></P>
</BODY>
<!-- EDGAR Validation Code: 770B7799 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ameh_ex99z1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ameh_ex99z1001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !U 5(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M88V\M%C;!)ZYSZ5SGB/2/[#UVYL Q98F&QCW'45ZC\*@H\+,5^\93NKB?B:
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M-E:L'=3,XZ%^U:X    P!VI:*F4G+=E**CL)BEHHJ1A1110 4444 )7 >./
M^H^(M:2ZLWB$8C"X<\YKT"B@#G?!.A7/A[0Q:7;(9-Y;*GBNBHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
